



Arterial Remodeling Technologies

**What the experts
are saying about
the Company and
its opportunity...**



“Unlike permanent stents, ART’s bioresorbable stents are designed to dismantle in vivo over an optimized time horizon.”

Thierry Chignon, PharmD
Investment Manager,
Matignon Technologies
(Paris); fmr. Consultant
to Commission of the
European Union, Medical
Device unit.



“No advantage for the permanency of stents has been demonstrated, and their presence may cause late thrombosis and chronic inflammation.”

Antoine Lafont, MD, PhD
Head, Interventional
Cardiology Department,
Georges Pompidou
Hospital (Paris); Former
Chairman, Interventional
Cardiology Group,
European Society of
Cardiology (ESC).



“Bioresorbable stents are emerging as an alternative to permanent metal stents in percutaneous coronary interventions.”

Michel Vert, PhD
Fmr. Dir., Center of
Research for Artificial
Biopolymers, CNRS
(Centre National de
Recherche Scientifique)
(Paris).

“...bioabsorbable devices are the future of coronary artery disease treatment.” Patrick W. Serruys, MD, PhD, professor, interventional cardiology, Thoraxcentre, Erasmus University Hospital, Rotterdam, The Netherlands (*Diagnostic and Invasive Cardiology*, Sept-Oct 2009 Issue, “Dissolving Stents May Offer New Options in the Next Decade”)

Vanishing stents

by Ronald C. Trahan

“Given the explosive growth and fast adoption rates exhibited by the coated stent market, the **bioresorbable** coronary stent market presents a compelling opportunity to participate in a potentially **disruptive, market-changing technology**,” says Dr. Thierry Chignon, Investment Manager with French venture capital firm Matignon Technologies and an early investor in Arterial Remodeling Technologies (ART). “Assuming an adoption rate similar to coated stents, by just the second year of commercialization the worldwide market opportunity for coronary bioresorbable stents could be in the neighborhood of \$3 billion.”

The approach being pursued by ART is to achieve temporary stenting of the traumatized angioplasty site to (1) prevent acute and chronic recoil; (2) allow the arterial wall to remodel through the use of a stent that dismantles; and (3) allow normal physiological healing processes to proceed.

ART’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre National de Recherche Scientifique), Montpellier, France; and, Descartes University, Paris.

“Our stents are designed to be both hemocompatible *and* bio-compatible, therein causing little or no inflammation while disappearing *over time*,” explains **Machiel van der Leest**, CEO of ART. Previously, Mr. van der Leest was Co-Founder and Chief Technology Officer of **Minvasys**. During his career he has developed and successfully introduced **15 Class III medical devices**, which require premarket approval and a scientific review to ensure safety and effectiveness.



“Stenting is the default device in percutaneous coronary interventions, but we believe the presence of stents should be brief, while facilitating healing.”
Machiel van der Leest,
CEO, ART

“We are convinced that the next generation of stents *must* be made of a biocompatible, non-aggressive material; they must have a transitory presence; *and* they must facilitate natural arterial wound-healing and remodeling,” says Mr. van der Leest. “It is important to note that **bioresorbability** is not an end unto itself, but rather a factor that allows our stent to dismantle and the artery to remodel.” ■